Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001641172-25-001869
Filing Date
2025-03-31
Accepted
2025-03-31 17:21:40
Documents
16
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 formpre14a.htm   iXBRL PRE 14A 764015
  Complete submission text file 0001641172-25-001869.txt   1583711

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE awh-20241231.xsd EX-101.SCH 5716
3 XBRL DEFINITION FILE awh-20241231_def.xml EX-101.DEF 9994
4 XBRL LABEL FILE awh-20241231_lab.xml EX-101.LAB 63820
5 XBRL PRESENTATION FILE awh-20241231_pre.xml EX-101.PRE 44666
19 EXTRACTED XBRL INSTANCE DOCUMENT formpre14a_htm.xml XML 221868
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-34810 | Film No.: 25795092
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)